No Data
No Data
Bio-Thera Solutions' Cancer Drug Gets EU Marketing Approval
Express News | European Medicines Agency (EMA) Approves Bio-Thera Solutions' Bat1706 (Avzivi®, Bevacizumab), a Biosimilar Referencing Avastin®
Bio-thera Solutions (688177.SH): Avzivi receives European Commission approval for listing.
Bio-Thera Solutions (688177.SH) announced on July 30th that it has recently received notification from the European Union Commission that Avzivi (BAT1706, Bevacizumab Injection) has been approved for marketing by the European Union Commission for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer.
Bio-Thera Solutions,: Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
What Bio-Thera Solutions, Ltd.'s (SHSE:688177) P/S Is Not Telling You
No Data